Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy

Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10(−5); 17% at 10(−6). All pati...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Hemasphere
Egile Nagusiak: Terpos, Evangelos, Kostopoulos, Ioannis V., Kastritis, Efstathios, Ntanasis-Stathopoulos, Ioannis, Migkou, Magdalini, Rousakis, Pantelis, Argyriou, Alexandra T., Kanellias, Nikolaos, Fotiou, Despina, Eleutherakis-Papaiakovou, Evangelos, Gavriatopoulou, Maria, Ziogas, Dimitrios C., Papanota, Aristea-Maria, Spyropoulou-Vlachou, Marilyn, Trougakos, Ioannis P., Tsitsilonis, Ourania E., Paiva, Bruno, Dimopoulos, Meletios A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wolters Kluwer Health 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6924563/
https://ncbi.nlm.nih.gov/pubmed/31976475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000300
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak